ACS Pharmacology & Translational Science
April 8, 2022
Grant C. Glatfelter, Michael R. Chojnacki, Shelby A. McGriff et al.
18 citations
Psychedelics are a class of drugs that produce unique subjective effects via agonist actions at the 5-hydroxytryptamine 2A receptor (5-HT2A). The 5-HT2A-mediated head twitch response (HTR) in rodents is used as a reliable proxy for psychedelic drug activity in humans, but existing methods for measuring HTRs require surgery or time-consuming visual scoring. In the present work, we validated a...
Psychiatric News
April 1, 2022
Michael Avissar, A. J. Ambrose
A growing body of research suggests that psychedelic compounds may be useful for treating patients with certain disorders. As highlighted by several sessions at the APA Annual meeting, there’s a growing renewed interest in psychedelics, which are compounds that induce changes in thought, perception, and mood, in the clinical and research communities. Classic psychedelics refer to a subset whose...
Clinical Toxicology
March 28, 2022
S. Ivory, J. Rotella, Jennifer L. Schumann et al.
Abstract Introduction 25B-NBOH is a synthetic hallucinogen closely related to the “NBOMe” family of N-substituted 2C phenethylamine derivatives. There have been no published reports documenting the clinical toxicity of NBOH derivatives. Case series Five patients presented to the Emergency Department (ED) with altered conscious state following exposure to powder sold as “powdered LSD” at a...
Frontiers in Psychiatry
March 25, 2022
David E. Nichols
65 citations
At first glance, it appears there is little difference between the molecular structures of methylenedioxymethamphetamine (MDMA), which has an N -methyl attached to its amino group, and methylenedioxyamphetamine (MDA), a primary amine that is recognized to have hallucinogenic activity. It is known from studies with other hallucinogenic amphetamines that N -methylation of hallucinogenic...
Comprehensive Psychiatry
March 24, 2022
Magdalena Wizła, Shane W. Kraus, Karol Lewczuk
Recently, there has been an increase in studies yielding evidence for psychedelics' anxiolytic and anti-depressive qualities. Preliminary evidence for treatment in substance addiction is also available. In our manuscript, we present a perspective on the possible effectiveness and mechanisms of action of psychedelics' introduction in the treatment of Compulsive Sexual Behavior Disorder (CSBD)...
Biomedicine & Pharmacotherapy
March 24, 2022
Francisco Madrid-Gambin, Alex Gomez-Gomez, Arnau Busquets-García et al.
14 citations
There has been a renewed interest in the potential use of psychedelics for the treatment of psychiatric conditions. Nevertheless, little is known about the mechanism of action and molecular pathways influenced by ayahuasca use in humans. Therefore, for the first time, our study aims to investigate the human metabolomics signature after consumption of a psychedelic, ayahuasca, and its connection...
Frontiers in Pharmacology
March 22, 2022
Enzo Tagliazucchi
20 citations
Psychedelics are drugs capable of eliciting profound alterations in the subjective experience of the users, sometimes with long-lasting consequences. Because of this, psychedelic research tends to focus on human subjects, given their capacity to construct detailed narratives about the contents of their consciousness experiences. In spite of its relevance, the interaction between serotonergic...
Frontiers in Neuroscience
March 17, 2022
Devon Stoliker, Gary F. Egan, Adeel Razi
19 citations
Evidence suggests classic psychedelics reduce the precision of belief updating and enable access to a range of alternate hypotheses that underwrite how we make sense of the world. This process, in the higher cortices, has been postulated to explain the therapeutic efficacy of psychedelics for the treatment of internalizing disorders. We argue reduced precision also underpins change to...
Metabolic Engineering Communications
March 11, 2022
Alexandra M. Adams, Nicholas A. Anas, Abhishek K. Sen et al.
21 citations
Interest in the potential therapeutic efficacy of psilocybin and other psychedelic compounds has escalated significantly in recent years. To date, little is known regarding the biological activity of the psilocybin pathway intermediate, norbaeocystin, due to limitations around sourcing the phosphorylated tryptamine metabolite for in vivo testing. To address this limitation, we first developed a...
Psychopharmacology
March 7, 2022
Aryan Sarparast, Kelan Thomas, Benjamin Malcolm et al.
85 citations
As MDMA and psilocybin continue to move through the FDA drug development process, this systematic review offers a compilation of existing research on psychiatric drug-drug interactions with MDMA or psilocybin.